Breaking News

Navigate BioPharma Services Launches Assay for Radioligand Therapies

New assay for quantifying pharmacodynamic markers of radioligand therapies (RLT) in tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, launched a new assay for quantifying pharmacodynamic markers of radioligand therapies (RLT) in tumors.    Navigate BioPharma’s new image-based test measures the changes in the cancer cells and the tissue after RLT. This assay utilizes multiplex immunofluorescence (mIF) combined with automated quantitative...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters